NEW YORK, March 6, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY
International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc.
(NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and
ArthroCare Corporation (NASDAQ: ARTC). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Regeneron Pharmaceuticals, Inc.
Analyst Notes
On February 27, 2014, Regeneron
Pharmaceuticals, Inc.'s (Regeneron) stock increased 0.61%, ending
the day at $338.54. Over the previous
three trading sessions, shares of Regeneron declined 2.61%,
compared to the Nasdaq Composite Index which increased 0.60% during
the same period. The full analyst notes on Regeneron
Pharmaceuticals, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03062014/REGN/report.pdf
--
DENTSPLY International Inc. Analyst
Notes
On February 18, 2014, DENTSPLY
International Inc. (DENTSPLY) reported its financial results for Q4
2013 and 2013. Q4 2013 net sales remained flat at $753.7 million on a year-on-year basis, while the
same gained 0.8% YoY to $2.95 billion
in 2013. Net income attributable to DENTSPLY for Q4 2013 was
$74.4 million, or $0.51 per diluted share, versus $126.8 million, or $0.88 per diluted share, in Q4 2012. For 2013,
net income attributable to DENTSPLY stood at $313.2 million or $2.16 per diluted share, compared with
$314.2 million or $2.18 per diluted share in 2012. Bret Wise, Chairman and CEO, commented, "We
continue to be pleased with the progress we have made in
accelerating earnings growth over the past few quarters, as we
realize benefits from our integration and cost savings activities.
Looking ahead, we see opportunities to continue to drive market
share growth across our global portfolio by leveraging our core
strategies of innovation, clinical education and sales force
effectiveness. We believe that global market conditions will
improve slightly in 2014 and, accordingly, we are expecting
adjusted earnings in the range of $2.45 to
$2.55 per share, representing growth in the range of 4% to
9% for the year." The full analyst notes on DENTSPLY International
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03062014/XRAY/report.pdf
--
AMAG Pharmaceuticals, Inc. Analyst
Notes
On February 25, 2014, AMAG
Pharmaceuticals, Inc. (AMAG) announced the appointment of
Edward Jordan as Senior Vice
President of sales and marketing. William
Heiden, President and CEO of AMAG, commented, "I have known
Ed for many years, and am confident that, with his deep experience
in pharmaceutical and device commercial leadership, he will be a
great addition to our executive team. Ed's ability to build and
lead top-performing commercial teams will be a great asset to AMAG
as we continue to drive market share growth and market expansion
for our current products." Jordan added, "I am very pleased to be
joining AMAG. It is an exciting time; coming off such a successful
2013 and well positioned for significant growth and success. I look
forward to leading the commercial team and contributing to the
company's goals of continuing to grow Feraheme and MuGard sales,
expanding the product portfolio and building a multi-product,
profitable specialty pharmaceutical company." The full analyst
notes on AMAG Pharmaceuticals, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03062014/AMAG/report.pdf
--
Cadence Pharmaceuticals Inc. Analyst
Notes
On February 27, 2014, Cadence
Pharmaceuticals Inc.'s (Cadence) stock increased 0.14%, ending the
day at $14.02. Over the previous
three trading sessions, shares of Cadence increased 0.36%, compared
to the Nasdaq Composite Index which increased 0.60% during the same
period. The full analyst notes on Cadence Pharmaceuticals Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03062014/CADX/report.pdf
--
ArthroCare Corporation Analyst
Notes
On February 27, 2014, ArthroCare
Corporation's (ArthroCare) stock increased 0.04%, ending the day at
$48.28. Over the previous three
trading sessions, shares of ArthroCare declined 0.35%, compared to
the Nasdaq Composite Index which increased 0.60% during the same
period. The full analyst notes on ArthroCare Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/03062014/ARTC/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review